Studie k hodnocení účinnosti a bezpečnosti systému INTERCEPT krevního systému pro erytrocyty u pacientů po komplexní kardiochirurgii (ReCePI)
Randomizovaná, dvojitě zaslepená, kontrolovaná, paralelní skupina, non-inferiorita, studie fáze III k vyhodnocení účinnosti a bezpečnosti krevního systému INTERCEPT pro červené krvinky u pacientů podstupujících komplexní kardiochirurgické výkony
The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red blood cells (RBCs) treated with the INTERCEPT Blood System (IBS) for Red Blood Cells compared to patients transfused with conventional RBCs.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a prospective, multicenter, randomized, double-blinded, active controlled, parallel-design, non-inferiority study.
Screening/Recruitment
In order to minimize the number of patients who enroll in the study but do not require RBC transfusion, only patients with a relatively high likelihood to receive a RBC transfusion as determined by the Investigator (e.g., patients receiving aspirin, clopidogrel (or analogs) and/or GPIIb/IIIa inhibitors), or patients with a TRUST Score of ≥3 will be eligible for enrollment. Patients ≥11 years of age undergoing complex cardiac surgery may be identified through pre-operative scheduling procedures in advance of their surgery.
Patients undergoing urgent or emergent cardiac surgery are eligible for the study, subject to institutional review board (IRB) approval of an appropriate informed consent process.
All potentially eligible patients will be approached for study consent/assent within 30 days prior to their surgical procedure. Subjects who consent/assent to the study will be assigned a subject ID number and undergo screening.
Screening will include documentation of the patient's pre-surgical exposure to radiographic contrast media and number of prior pregnancies (females). Screening data may be derived from the medical record when performed within 30 days prior to their surgical procedure. Eligibility status and other study data including all TRUST components will be entered into the clinical database via an electronic data capture (EDC) system using electronic case report forms (eCRFs). Patients who fail eligibility for any or multiple inclusion/exclusion criteria may be rescreened for eligibility closer to the time of surgery.
Randomization and Blinding
Eligible subjects will be randomized up to 7 days before or on the day of scheduled surgery (Day 0). An Interactive Web Response System (IWRS) will be used for electronic randomization of eligible patients. Randomization (in 1:1 ratio for Test:Control) stratified by site, pre-existing renal impairment (baseline sCr ≥1.2 mg/dL vs. < 1.2 mg/dL), and cardiac surgery group (more at risk for renal complications vs. less at risk) will be employed. Screened subjects who receive a red cell transfusion prior to randomization will no longer be considered for randomization, and their participation in the study will end. Patients may be rescreened for eligibility closer to the time of surgery.
Treatment
Once a subject is randomized, only study RBCs (Test or Control, per the subject's randomization) should be dispensed and transfused during the acute transfusion support period (Day 0 to Day 7 post surgery, hospital discharge, or death, whichever is first), as clinically indicated and determined by the treating physician.
In rare exceptions where study RBCs are unavailable or patient's need for RBC transfusions exceeds the quantity of study RBCs in inventory at the hospital blood bank (e.g., during a Massive Transfusion Protocol), a transfusion using non-study RBC (conventional) may be given to provide the patient with an appropriate and necessary treatment. In this case, a protocol deviation should be documented. If a study RBC transfusion is given after randomization before surgery commences, a protocol deviation should also be documented.
Treatment assessments will be divided into an acute transfusion support period starting the day of surgery (Day 0 up to Day 7) during which study RBC (Test or Control) are administered, a post-surgical follow-up period of a minimum of 28 days after the last study transfusion to collect additional safety data, a clinical assessment at day 30 after surgery specifically for mortality and RRT status, and a visit at day 75 (±15) after the last study transfusion to assess mortality and RRT status, and collect samples for serological screening for antibodies specific to INTERCEPT RBCs.
In all patients, anesthesia and surgical procedures will be performed according to the local standards of care. Following the acute transfusion support period, subjects may receive conventional RBC components if additional transfusions are needed, as indicated by their treating physician.
Study Assessments: Monitoring and Follow-up
Baseline through Acute Transfusion Support Period (Pre-Op Day -1 up to Post-Op Day 7):
A screen for antibodies specific for INTERCEPT RBCs should be performed every time that a routine IAT is performed during the acute 7-day study transfusion period.
A blood sample for sCr will be taken at 48 ±4 hours after completion of surgery for both transfused and non-transfused subjects., A sCr will be determined on a daily basis during the acute transfusion support period up to 7 days post-surgery. Other parameters including additional sCr will be collected on eCRFs only when available in the medical record.
Randomized subjects who do not receive an RBC transfusion following randomization within the first 48 hours after surgery will be discontinued from the study and replaced.
Daily sCr assessments will be recorded up to and including 48 ±4 hours for transfused and non-transfused subjects. Other post baseline laboratory parameters and adverse events (AEs) will not be collected for non-transfused subjects. Vital status will be reported for randomized and non-transfused subjects at the time of discontinuation.
Hemodynamic and laboratory measures will be assessed pre-operatively (Day -1, Baseline) and daily as available in the medical record from post operative Day 1 through Day 7, hospital discharge or death, whichever occurs first. If a subject is discharged prior to Day 7 but returns to the study site for a standard of care visit on Day 7, blood samples should be obtained on that day for a complete blood count and sCr determination.
Hemodynamic parameters that will be collected if available, include heart rate, blood pressure, mean arterial pressure, central venous pressure (CVP), and peripheral oxygen saturation via pulse oximetry probe.
Laboratory parameters that will be captured on eCRFs include BUN, creatinine (sCr), AST, ALT, fibrinogen, bilirubin, troponin, hemoglobin, and platelet counts.
Transfusion reactions (TRs), adverse events (AEs) and serious adverse events (SAEs) will be assessed on a daily basis and documented in the eCRF from the start of surgery or the start of the first study transfusion (whichever is first) through post-operative Day 7 and as available through day 28 after the last study transfusion. Vital status will be reported for randomized and non-transfused subjects at the time of discontinuation.
NOTE: The following applies to randomized transfused subjects only.
Post-operative Day 8 (or Post-discharge, if earlier) through 28 Days After Last Study Transfusion:
Subjects will be monitored for TRs, AEs and SAEs following the 7-day acute transfusion support period, through 28 days after the last study transfusion or death, whichever occurs first, according to the local standard of care. In an outpatient setting, weekly telephone surveillance calls to the subject will be performed in order to collect safety events until the next follow-up visit.
28 (±3) Days After Last Study Transfusion or Premature Discontinuation from study:
Subjects who have been discharged should be scheduled for the follow up visit 28 (±3) days after the last study transfusion to obtain additional safety information, including patient-reported AEs/ SAEs; laboratory results including sCr, DAT/ IAT; a sample for HLA antibodies and antibodies specific to INTERCEPT RBCs will be obtained. All randomized subjects who receive any study RBC transfusion must have their vital status documented at this visit, or earlier, if the subject dies prior to the visit. If a subject has been discharged, other safety information (e.g., AEs and SAEs) may be obtained through medical records, the subject's physician, or a telephone interview with either the subject or a family member.
30 Days After Surgery:
All randomized subjects who receive a study RBC transfusion must have their vital status and need for RRT (defined as hemodialysis or peritoneal dialysis) documented at Day 30 after surgery. RRT that is provided prophylactically during surgery while patient is on a bypass machine (the pump), does not meet this endpoint. The vital status and RRT assessment on Day 30 can be performed either from the medical records, from a phone call to the subject or family, or during the visit 28±3 days after the last study transfusion (only if the last study transfusion was given at day 2 or later in the acute transfusion support period).
End of Study: 75 (±15 Days) After last Study Transfusion:
75 (±15) days after the last study transfusion (End of Study), serum samples for antibodies specific for INTERCEPT RBCs will be obtained, either in hospital, at a clinic visitor or offsite. Mortality and the need for RRT will be assessed
Data and Safety Monitoring Board (DSMB)
The study data and safety will be monitored by an independent Data and Safety Monitoring Board (DSMB). The primary mission of the DSMB is to ensure patient safety and protocol compliance for data collection. The DSMB will be assembled by the Sponsor and composed of transfusion medicine and other experts as per the DSMB charter. DSMB members will be independent of the Sponsor.
Interim Analysis and Early Stopping Rule
Aside from the blinded interim analysis for sample size re-estimation performed in October 2021, no other interim analysis is planned for this study to compare treatment differences with respect to efficacy or safety at any time prior to the completion of the study. Specific stopping rules, defined for safety considerations, are defined in Section 4.6 of the protocol.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
California
-
Los Angeles, California, Spojené státy, 90095
- University of California Los Angeles
-
Stanford, California, Spojené státy, 94305
- Stanford
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Hospital
-
-
Connecticut
-
Bridgeport, Connecticut, Spojené státy, 06610
- Bridgeport Hospital
-
New Haven, Connecticut, Spojené státy, 06510
- Yale New Haven Hospital
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32611
- University of Florida
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- Emory
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40356
- University of Kentucky
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Henry Ford Health System
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo-Rochester
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Health System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19140
- Temple
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- University of Texas Southwestern
-
Houston, Texas, Spojené státy, 77030
- Houston Methodist
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Health System
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Age ≥ 11 years of age
-
Weight ≥ 40 kg
-
Scheduled complex cardiac surgery or thoracic aorta surgery. The procedure may be performed either on or off cardiopulmonary bypass machine (CBP or "pump"). For the purposes of this protocol "Repeat procedure" means that the subject had a previous cardiac surgery. Procedures that qualify as complex cardiac surgery include but are not limited to, the following:
-
Single Vessel Coronary Artery Bypass Graft, first or repeat procedure
-
Multiple Coronary Artery Bypass Grafts, first or repeat procedure
-
Single Valve Repair or Replacement, first or repeat procedure
-
Multiple Valve Repair or Replacement, first or repeat procedure
-
Surgery involving both Coronary Artery Bypass Graft(s) and Valve Repair(s), first or repeat procedure
-
One or more of the following procedures, with or without Coronary Bypass Graft(s):
- left ventricular aneurysm repair
- ventricular and/or atrial septal defect repairs
- Batista procedure (surgical ventricular remodeling)
- surgical ventricular restoration
- congenital cardiac defect repair
- aortic procedures
- other cardiac surgery or thoracic aorta surgery types with a high probability of bleeding
-
-
TRUST probability score (Alghamdi, Davis et al. 2006) ≥ 3, or currently on a regimen of aspirin (any dose), clopidogrel (or analogs) and/or GPIIb/IIIa inhibitors or at a high probability for need of a transfusion during or after surgery at the discretion of the Investigator
-
Female subjects of child-bearing potential must meet the 2 criteria below at screening:
- Negative serum or urine pregnancy test
- Use at least one method of birth control that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner
-
Signed and dated informed consent/assent form
Exclusion Criteria:
- Confirmed positive baseline serum/plasma antibody specific to INTERCEPT RBCs (S-303 specific antibody) screening panel prior to randomization.
- Pregnant or breast feeding
- Refusal of blood products or other inability to comply with the protocol in the opinion of the Investigator or the treating physician
- Treatment with any medication that is known to adversely affect RBC viability, such as, but not limited to dapsone, levodopa, methyldopa, nitrofurantoin, and its derivatives, phenazopyridine and quinidine.
- Planned cardiac transplantation
- Active autoimmune hemolytic anemia
- Left ventricular assist device (LVAD) or extracorporeal membrane oxygenation (ECMO) support pre operatively or planned need post-operatively
- Cardiogenic shock requiring pre-operative placement of an intra-aortic balloon pump (IABP) (NOTE: IABP done for unstable angina or prophylactically for low ejection fraction is not excluded).
- Planned use of autologous or directed donations.
- RBC transfusion during current hospitalization prior to enrollment and randomization (within 7 days).
- Participation in an interventional clinical study concurrently or within the previous 28 days. This includes investigational blood products, pharmacologic agents, imaging materials (including dyes), surgical techniques, or devices. Observational studies of FDA cleared or approved products or nutrition, psychology, or socioeconomic issues are not grounds for exclusion
- Patients with a current diagnosis of either chronic kidney disease or acute kidney injury and with sCr ≥1.8 mg/dL at screening and patients requiring RRT. (NOTE: If sCr at screening is <1.8 mg/dL, a patient with a diagnosis of chronic or acute kidney injury alone is not excluded).
- Patients with a current diagnosis of either chronic or acute hepatic insufficiency and with a total serum bilirubin ≥ 2.0 mg/dL (≥34.2 µmol/L). (NOTE: If total serum bilirubin at screening is <2.0 mg/dL, a patient with a diagnosis of chronic or acute hepatic failure alone is not excluded).
- Pre-existing antibody(ies) to RBC antigens that may make the provision of compatible study RBC components difficult.
- History of TRs requiring washed RBCs, volume reduced RBC, or RBCs with additive solution removed.
- Patients with documented IgA deficiency or a history of severe allergic reactions to blood products.
- Patients who require gamma-irradiated RBC blood components.
- Positive DAT as defined below:
A polyspecific DAT reaction strength > 2+, or
A polyspecific DAT (any strength) in conjunction with pan-reactivity with a commercial IAT antibody screening panel that precludes the identification of underlying alloantibodies or indicates the presence of autoantibody
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: INTERCEPT (test)
The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician. |
Pathogen reduced RBCs |
|
Aktivní komparátor: Conventional (Control)
The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician. |
Conventional RBCs |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Patients Who Have Received at Least One Study Transfusion With a Diagnosis of Renal Impairment Defined as:
Časové okno: Within 48±4 hours of the end of surgery
|
Any raised serum creatinine (sCr) level, occurring after transfusion of a study RBC, of ≥0.3 mg/dL (or 26.5 µmol/L) from the pre-surgery baseline within 48±4 hours of the end of surgery. |
Within 48±4 hours of the end of surgery
|
|
Percentage of Patients With Related Adverse Events
Časové okno: From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Percentage of patients with any treatment-emergent adverse events (TEAEs) possibly, probably or definitely related to study RBC transfusion through 28 days after the last study transfusion. |
From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
|
Percentage of Patients With Treatment Emergent Antibodies
Časové okno: From the start of the first study transfusion to 75 days after the last study transfusion (between 76-82 days depending on the day of the last study transfusion).
|
Percentage of patients with treatment-emergent antibodies with confirmed specificity to INTERCEPT RBCs by the end of study. |
From the start of the first study transfusion to 75 days after the last study transfusion (between 76-82 days depending on the day of the last study transfusion).
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Patients With a Diagnosis of Stage I, II or III Acute Kidney Injury
Časové okno: 7 days
|
The percentage of patients with a diagnosis of stage I, II, or III Acute Kidney Injury (KDIGO 2012) by day 7 post surgery, as defined by the change in serum creatinine (sCr) from baseline and the need for renal replacement therapy, i.e. clinical worsening of outcome from Stage I to Stage III. Stage I: sCr 1.5-1.9 times baseline within 7 days after surgery or > or=0.3 mg/dl (> or= 26.5 micromol/L) increase within 48 hrs of surgery; Stage II: sCr 2.0-2.9 times baseline within 7 days after surgery; Stage III: sCr 3.0 times baseline within 7 days after surgery or increase in sCr to > or=4.0 mg/dl (> or=353.6 micromol/L) or initiation of renal replacement therapy. |
7 days
|
|
Mortality or the Need for RRT
Časové okno: 30 days
|
Mortality or the need for RRT by 30 days post surgery |
30 days
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With Treatment-emergent (TE) Immunization to RBC Alloantigens
Časové okno: From the start of the first study transfusion to 28 after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Treatment-emergent (TE) immunization to RBC alloantigens through 28 ± 3 days after the last study transfusion. |
From the start of the first study transfusion to 28 after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
|
Number of Participants With Transfusion Reactions (TR)
Časové okno: From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Transfusion reactions (as defined by the CDC National Healthcare Safety Network) through 28 days after the last study transfusion |
From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
|
Number of Participants With Serious Adverse Events (SAEs)
Časové okno: From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Treatment-emergent SAEs through 28 days after the last study transfusion |
From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
|
Number of Participants With Treatment Emergent Immunization to HLA Alloantigens Through 28 ± 3 Days From After the Last Study Transfusion
Časové okno: 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Treatment emergent HLA Class 1 or Class 2 antibodies at high cutoff values |
28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
|
Number of Participants With Treatment Emergent AEs Through 28 Days After the Last Study Transfusion.
Časové okno: From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Treatment emergent adverse events through 28 days after the last study transfusion. |
From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Richard J Benjamin, MD, Cerus Corporation
Publikace a užitečné odkazy
Obecné publikace
- Karim C, Panigrahi A, Pearl RG, Sodha NR, Beaver TM, Pelletier JPR, Nuttall GA, Reece TB, Erickson A, Hedrick T, Liu K, Bentow S, Corash L, Mufti N, Varrone J, Benjamin RJ. Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells. Transfusion. 2025 Feb;65(2):344-353. doi: 10.1111/trf.18117. Epub 2024 Dec 25.
- Sekela ME, Snyder EL, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, Beaver TM, Pelletier JPR, Gorham JD, McNeil JS, Sniecinski RM, Pearl RG, Nuttall GA, Sarode R, Reece TB, Benjamin RJ; and the ReCePI Study Collaborators. Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial. Anesthesiology. 2025 Nov 1;143(5):1196-1210. doi: 10.1097/ALN.0000000000005716. Epub 2025 Aug 12.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CLI 00125
- HHSO100201600009C (Jiné číslo grantu/financování: Biomedical Advanced Research and Development Authority (BARDA))
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Submit protocol, SAP and ICF.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .